Date:	--/--/-- --:--:--
Event Id:	E5CZL3OTR
Action Type:	ACQUISITION
Action Status:	ANNOUNCED
Acquirer Symbol:
Target Symbol:	ITCI
Updated:	--/--/-- --:--:--
Purchase Price Per Share:	132
Price Per Share Currency:	USD
News References:	https://www.sec.gov/Archives/edgar/data/1567514/000119312525028672/d921418ddefm14a.htm

Action Notes

Johnson & Johnson and Intra-Cellular Therapies, Inc announced today that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies, a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, for $132.00 per share in cash for a total equity value of approximately $14.6 billion. The closing of the transaction is expected to occur later this year subject to applicable regulatory approvals, approval by Intra-Cellular Therapies' stockholders and other customary closing conditions for a transaction of this type. Following completion of the transaction, Intra-Cellular Therapies' common stock will no longer be listed for trading on the Nasdaq Global Select Market. The Intra-Cellular special shareholder meeting to vote on the transaction will be held on 03/27.